EGFR and non-small cell lung carcinoma: In the case of TKIs, an important challenge lies in balancing treatment benefit with treatment-related toxicities that emanate from unselective inhibition of other ERBB family members; the latest efforts to target HER2-mutant NSCLC have employed highly selective HER2 inhibitors.